M&A / Deals Symeres and Ambagon collaborate for colorectal cancer molecules Pharmaceutical Business ReviewThe partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins.M&A / DealsOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Business Review The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins. M&A / DealsOncologyRead full story Post navigation Previous: Telomir seeks FDA approval for Telomir-1 to treat breast cancerNext: Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
